Aeton Therapeutics, Inc.
Publicly observedBurlingame, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Burlingame | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Aeton Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | MC2DMP4NVUC7 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant17 Sept 2026Publicly observed
NIH SBIR/STTR award: Human CGAS inhibitors to treat neurodegeneration in Alzheimer's disease
USD 932,681.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.